MedTrace Logo

Treatment of Influenza and ARVI in Children by Kagocel ®

NCT04651491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-12-03

No results posted yet for this study

Summary

This study examined the etiology of acute respiratory viral infections (ARVI) during the 2015-2016 season, evaluated the statistics of the incidence of influenza and ARVI in this period (epidemiology: severity of the disease and bacterial exacerbations; demographics of patients; duration and timing of treatment; safety; quality of treatment), and evaluated the effectiveness of complex therapy with an emphasis on the using of interferon inducers in hospitalized children aged 3 to 11 years.

Conditions

  • Influenza
  • Acute Upper Respiratory Infection

Interventions

DRUG

Kagocel

The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study. Kagocel administration: 1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days. 2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days.

Sponsors & Collaborators

  • Nearmedic Plus LLC

    lead INDUSTRY

Principal Investigators

  • Irina Babachenko, Professor, Dr. habilitated · Research Institute of Children's Infections of the Federal Medical and Biological Agency,

Eligibility

Min Age
3 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-11
Primary Completion
2016-05-05
Completion
2016-09-28

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651491 on ClinicalTrials.gov